Omega-3 supplements for patients in chemotherapy and/or radiotherapy: A systematic review

Imagem de Miniatura
Arquivos
art_SILVA_Omega3_supplements_for_patients_in_chemotherapy_andor_radiotherapy_2015.PDF (689.57 KB)
Citações na Scopus
107
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CHURCHILL LIVINGSTONE
Autores
SILVA, Juliana de Aguiar Pastore
FABRE, Maria Emilia de Souza
Citação
CLINICAL NUTRITION, v.34, n.3, p.359-366, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background & aims: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in vitro and in vivo, used along with anticancer drugs, have improved cancer treatment outcome. Clinical studies have reported positive results with omega-3 supplements in oncologic patients. We summarized only randomized controlled clinical trials involving the administration of DHA and/or EPA during chemotherapy and/or radiotherapy to assess the effects on treatment outcomes. Methods: We conducted a systematic literature search using specific terms. Of 157 publications, 10 were selected on the basis of their methodological quality, according to the Oxford Quality Scale and the Cochrane Concealment Assessment. Outcome included body weight and composition, peripheral neuropathy, immune, inflammatory and oxidative status, quality of life, and membrane omega-3 fatty acids incorporation. Results: Treatment regimens included radiotherapy (1), chemotherapy (8), and chemoradiotherapy (1). The number of patients ranged from 11 to 92 and the daily dose of EPA and/or DHA from 600 mg to 3.6g. For high quality methodology studies only, the combination of omega-3 fatty acids supplements with conventional chemotherapy was beneficial. None of the studies reported a worse outcome for the supplement patients. Conclusions: There are beneficial effects of omega-3 fatty acids supplements in patients undergoing chemotherapy and/or radiotherapy on different outcomes, being the preservation of body composition the most evident. Some important outcome like decrease tumor size and prolonging patient survival, are not observed.
Palavras-chave
Omega-3 fatty acids, Eicosapentaenoic acid, Docosahexaenoic acid, Chemotherapy, Radiotherapy, Oncologic treatment
URI
https://observatorio.fm.usp.br/handle/OPI/11655
Referências
  1. Altenburg JD, 2009, MOL CANCER RES, V7, P1013, DOI 10.1158/1541-7786.MCR-08-0385
  2. Awad S, 2012, CLIN NUTR, V31, P74, DOI 10.1016/j.clnu.2011.08.008
  3. Bonatto SJR, 2012, LIPIDS, V47, P383, DOI 10.1007/s11745-011-3643-0
  4. Calder P. C., 2012, J NUTR, V142, P592, DOI 10.3945/JN.111.155259
  5. Calder PC, 2008, CURR OPIN CLIN NUTR, V11, P91, DOI 10.1097/MCO.0b013e3282f449f6
  6. Calviello G, 2005, CANCER CHEMOTH PHARM, V55, P12, DOI 10.1007/s00280-004-0846-6
  7. Colomer R, 2007, BRIT J NUTR, V97, P823, DOI 10.1017/S000711450765795X
  8. Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
  9. Deng MH, 2013, TUMOR BIOL, V34, P2809, DOI 10.1007/s13277-013-0839-3
  10. Faber J, 2013, CLIN NUTR, V32, P338, DOI 10.1016/j.clnu.2012.09.009
  11. Fekete K, 2009, AM J CLIN NUTR, V89, P2070
  12. Finocchiaro C, 2012, BRIT J NUTR, V108, P327, DOI 10.1017/S0007114511005551
  13. Ghoreishi Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-355
  14. Granci V, 2013, BRIT J NUTR, V109, P1188, DOI 10.1017/S000711451200308X
  15. Guarcello M., 2007, NUTR THER METAB, V25, P25
  16. Gurzell EA, 2014, PROSTAG LEUKOTR ESS, V91, P87, DOI 10.1016/j.plefa.2014.04.001
  17. Hajjaji N, 2013, CANCER TREAT REV, V39, P473, DOI 10.1016/j.ctrv.2012.07.001
  18. Higgins JP, 2011, BMJ-BRIT MED J, V18, P343, DOI 10.1136/BMJ.D5928
  19. Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
  20. Jing KP, 2013, ANTI-CANCER AGENT ME, V13, P1162
  21. Jordan A, 2003, EUR J NUTR, V42, P324, DOI 10.1007/s00394-003-0427-1
  22. Laviano A, 2013, CURR OPIN CLIN NUTR, V16, P156, DOI 10.1097/MCO.0b013e32835d2d99
  23. Maheo K, 2005, FREE RADICAL BIO MED, V39, P742, DOI 10.1016/j.freeradbiomed.2005.04.023
  24. Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
  25. Merendino N, 2013, BIOMED RES INT, DOI 10.1155/2013/310186
  26. Mocellin MC, 2013, LIPIDS, V48, P879, DOI 10.1007/s11745-013-3816-0
  27. Murphy RA, 2012, CURR OPIN CLIN NUTR, V15, P246, DOI 10.1097/MCO.0b013e328351c32f
  28. Murphy RA, 2011, CANCER-AM CANCER SOC, V117, P1775, DOI 10.1002/cncr.25709
  29. Murphy RA, 2011, CANCER-AM CANCER SOC, V117, P3774, DOI 10.1002/cncr.25933
  30. Ravacci GR, 2013, J NUTR BIOCHEM, V24, P505, DOI 10.1016/j.jnutbio.2012.02.001
  31. Sanchez-Lara K, 2014, CLIN NUTR, V33, P1017, DOI 10.1016/j.clnu.2014.03.006
  32. Siddiqui RA, 2011, BIOFACTORS, V37, P399, DOI 10.1002/biof.181
  33. Silva JDP, 2012, NUTR CANCER, V64, P267, DOI 10.1080/01635581.2012.643133
  34. Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
  35. Trabal J, 2010, NUTR HOSP, V25, P736, DOI 10.3305/nh.2010.25.5.4616
  36. van der Meij BS, 2012, EUR J CLIN NUTR, V66, P399, DOI 10.1038/ejcn.2011.214
  37. van der Meij BS, 2010, J NUTR, V140, P1774, DOI 10.3945/jn.110.121202

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/35
Artigos e Materiais de Revistas Científicas - ODS/03